Prevention of neointimal hyperplasia after coronary artery bypass graft via local delivery of sirolimus and rosuvastatin: network pharmacology and in vivo validation
Journal of Translational Medicine · 2024
DOI: 10.1186/s12967-024-04875-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Translational Medicine, 2024. Verfasst von Ji-Yeon Ryu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Surgery, Department of Thoracic and Cardiovascular Surgery, Severance Cardiovascular Hospital, Yonsei University College o…. Hauptthemen laut MEDLINE: Sirolimus, Drugs, Chinese Herbal. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Industry Development Institute, Ministry of Education, Ministry of Science and ICT, South Korea.
Abstract (Originalsprache)
Background
Coronary artery bypass graft (CABG) is generally used to treat complex coronary artery disease. Treatment success is affected by neointimal hyperplasia (NIH) of graft and anastomotic sites. Although sirolimus and rosuvastatin individually inhibit NIH progression, the efficacy of combination treatment remains unknown.
Methods
We identified cross-targets associated with CABG, sirolimus, and rosuvastatin by using databases including DisGeNET and GeneCards. GO and KEGG pathway enrichment analyses were conducted using R studio, and target proteins were mapped in PPI networks using Metascape and Cytoscape. For in vivo validation, we established a balloon-injured rabbit model by inducing NIH and applied a localized perivascular drug delivery device containing sirolimus and rosuvastatin. The outcomes were evaluated at 1, 2, and 4 weeks post-surgery.
Results
We identified 115 shared targets between sirolimus and CABG among databases, 23 between rosuvastatin and CABG, and 96 among all three. TNF, AKT1, and MMP9 were identified as shared targets. Network pharmacology predicted the stages of NIH progression and the corresponding signaling pathways linked to sirolimus (acute stage, IL6/STAT3 signaling) and rosuvastatin (chronic stage, Akt/MMP9 signaling) . In vivo experiments demonstrated that the combination of sirolimus and rosuvastatin significantly suppressed NIH progression. This combination treatment also markedly decreased the expression of inflammation and Akt signaling pathway-related proteins, which was consistent with the predictions from network pharmacology analysis.
Conclusions
Sirolimus and rosuvastatin inhibited pro-inflammatory cytokine production during the acute stage and regulated Akt/mTOR/NF-κB/STAT3 signaling in the chronic stage of NIH progression. These potential synergistic mechanisms may optimize treatment strategies to improve long-term patency after CABG. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Surgery, Department of Thoracic and Cardiovascular Surgery, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, 03722, South Korea.
- School of Mechanical Engineering, Yonsei University, Seoul, 03722, South Korea.
- Department of Mechanical Engineering, University of Minnesota, Minneapolis, MN, 55455, USA.
- Division of Cardiovascular Surgery, Department of Thoracic and Cardiovascular Surgery, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, 03722, South Korea. ynyoun@yuhs.ac.
Förderung
- Korea Health Industry Development Institute
- Ministry of Education
- Ministry of Science and ICT, South Korea
Zitieren
APA
Ryu, J. Y., Jang, E. H., Lee, J., Kim, J. H., & Youn, Y. N. (2024). Prevention of neointimal hyperplasia after coronary artery bypass graft via local delivery of sirolimus and rosuvastatin: network pharmacology and in vivo validation. Journal of Translational Medicine. https://doi.org/10.1186/s12967-024-04875-8
Vancouver
Ryu JY, Jang EH, Lee J, Kim JH, Youn YN. Prevention of neointimal hyperplasia after coronary artery bypass graft via local delivery of sirolimus and rosuvastatin: network pharmacology and in vivo validation. Journal of Translational Medicine. 2024. doi:10.1186/s12967-024-04875-8
BibTeX
@article{Ryu2024,
author = {Ryu, Ji-Yeon and Jang, Eui Hwa and Lee, JiYong and Kim, Jung-Hwan and Youn, Young-Nam},
title = {Prevention of neointimal hyperplasia after coronary artery bypass graft via local delivery of sirolimus and rosuvastatin: network pharmacology and in vivo validation},
journal = {Journal of Translational Medicine},
year = {2024},
doi = {10.1186/s12967-024-04875-8}
}
EUVIMED